New Covid 19 treatment, page-314

First 314 Last

Share
Profile

Follow
RickyH

457 Posts.

265

04/10/21

13:23

Post #: 56545722
Share

Originally posted by LearningEachDay: ↑

At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012.

That p value tells you that the sample size was sufficient. If there was a smaller difference between treatment and placebo, they may have needed a larger sample size to still show statistical significance.

Guess what? MSB trial also had impressive p values, even with small sample sizes, on patients under 65. Possible because baseline mortality was high, and difference between treated and controls was large. Problem is it wasn't in primary endpoint with 30 day mortality, but instead in secondary endpoints at 60 days and 90 days. I am not an expert on multiplicity but won't deny it could have played a role in request for another trial. Still, we're not talking about any old random secondary endpoint, but a longer term mortality endpoint. Does anyone really expect the beneficial effect to disappear when we have a 60 day mortality primary endpoint in a new trial, where we look at Dex vs Dex+Rex?

Some argue post hoc data dredging, but the under 65 analysis was prespecified and sample size was still large enough to show statistical significance. Granted, p value was p.048, as opposed to the really great p values of around 0.01 or less that we would hope for.

Analysis with dexamethasone was very impressive, with very low p values <0.01, but post-hoc analysis, nobody is denying that. Still, does this not look incredibly promising for what a new trial will show?

Expand

Thanks for that. Great to have a reply without the personal swipes.

MSB Price at posting: $1.63 Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

What's causing the cost-of-living crisis, and how to navigate it

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war